28–29 August 2025 Mauno Koivisto Centre, BioCity, Turku, Finland
Thank you everyone for making the event once again a success!
The 34th BioCity Symposium focuses on drug development across a range of disease groups and on various drug modalities. Despite of significant breakthroughs in medicine, there are still numerous conditions for which there are no curative treatments, or even therapies that would effectively slow down the disease progression. Therefore, novel drug targets need to be identified and new drugs need to be discovered to target the disease-driving mechanisms. In this symposium, we will focus on academic drug discovery and on mechanisms how the promising new compounds identified in academic setting can be converted to commercially viable industrial drug development programs. The symposium will also cover exciting new approaches to select the most suitable patient populations for the emerging therapies.
Invited Speakers
Petri Bono, Faron Pharmaceuticals, Finland Anniina Färkkilä, University of Helsinki, Finland Carmen Galan, University of Bristol, UK Nathanael S. Gray, Stanford University, USA Christian Heinis, École Polytechnique Fédérale de Lausanne, Switzerland Teemu Junttila, Genentech, USA David Leppert, University Hospital Basel, Switzerland Richard Marais, Oncodrug Ltd, UK Silvia Marsoni, IFOM, Italy Maarit Merla, Finnish Drug Discovery Center Ltd, Finland Francesca E. Morreale, The Francis Crick Institute, UK Hélder A. Santos, University of Groningen, The Netherlands
Organizing committee
Laura Airas Maija Hollmén Reko Leino Olli Pentikäinen Jessica Rosenholm Jukka Westermarck (chair)
